- Home
- PETS vs EYEN Comparison
PETS vs EYEN Comparison
Compare PETS & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- EYEN
- Stock Information
- Founded
- PETS 1996
- EYEN 2014
- Country
- PETS United States
- EYEN United States
- Employees
- PETS N/A
- EYEN N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- EYEN Health Care
- Exchange
- PETS Nasdaq
- EYEN Nasdaq
- Market Cap
- PETS 62.8M
- EYEN 2.9M
- IPO Year
- PETS N/A
- EYEN 2018
- Fundamental
- Price
- PETS $3.29
- EYEN $15.75
- Analyst Decision
- PETS Sell
- EYEN Hold
- Analyst Count
- PETS 2
- EYEN 4
- Target Price
- PETS $3.35
- EYEN $2.00
- AVG Volume (30 Days)
- PETS 142.3K
- EYEN 9.4M
- Earning Date
- PETS 08-05-2025
- EYEN 08-11-2025
- Dividend Yield
- PETS N/A
- EYEN N/A
- EPS Growth
- PETS N/A
- EYEN N/A
- EPS
- PETS 0.02
- EYEN N/A
- Revenue
- PETS $247,010,000.00
- EYEN $67,063.00
- Revenue This Year
- PETS N/A
- EYEN $7,680.45
- Revenue Next Year
- PETS N/A
- EYEN $315.38
- P/E Ratio
- PETS $192.80
- EYEN N/A
- Revenue Growth
- PETS N/A
- EYEN 663.82
- 52 Week Low
- PETS $2.90
- EYEN $0.85
- 52 Week High
- PETS $6.85
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- PETS 39.83
- EYEN 77.63
- Support Level
- PETS $3.13
- EYEN $7.50
- Resistance Level
- PETS $3.44
- EYEN $14.33
- Average True Range (ATR)
- PETS 0.18
- EYEN 2.92
- MACD
- PETS -0.02
- EYEN 0.86
- Stochastic Oscillator
- PETS 29.63
- EYEN 90.51
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.